Hepatocellular Carcinoma Surveillance and Survival in a Contemporary Asia-Pacific Cohort

作者：Ryan Yanzhe Lim, Benjamin Koh, Cheng Han Ng, Anand V. Kulkarni, Ken Liu, Karn Wijarnpreecha, Beom Kyung Kim, Mark Muthiah, Sung Won Lee, Ming‐Hua Zheng, Takumi Kawaguchi, Hirokazu Takahashi, Daniel Q. Huang, Padaki Nagaraja Rao, Mithun Sharma, D. Nageshwar Reddy, Charlotte Kench, Shirin Salimi, Abdul‐Hamid Sabih, Majd B. Aboona, Claire Faulkner, Pooja Rangan, Nicholas Syn, Margaret LP Teng, M. Da Costa, Hae Lim Lee, Ming‐Hua Zheng, Chong-ming Zheng, Masahito Nakano, Toru Nakamura, Keisuke Amano, Takuya Kuwashiro · 发表于：JAMA Network Open · 年份：2025 · DOI：10.1001/jamanetworkopen.2025.20294 · 被引用次数：13 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver Disease Diagnosis and Treatment、Hepatitis B Virus Studies

Importance: The etiologies of hepatocellular carcinoma (HCC) are changing. It is unclear whether the benefit of surveillance for people with HCC remains consistent given the changing etiologies of the disease. Objective: To evaluate the association of HCC surveillance with the survival rates of a large contemporary cohort of people with HCC. Design, Setting, and Participants: This was a retrospective cohort study that included participants with HCC between January 2008 and August 2023. Participants with HCC were identified from 5 international sites in Singapore, Japan, South Korea, and Australia. A total of 1185 adult participants were included in this cohort study. All included participants had available information regarding the presence or absence of surveillance. Data were analyzed from June 26, 2024, to March 6, 2025. Main Outcomes and Measures: The primary outcome was overall survival rates with HCC surveillance vs no surveillance. Multivariable restricted mean survival time (RMST) analyses with lead-time bias adjustments were conducted to assess overall survival. Results: Of 1185 participants with HCC, 921 (77.7%) were male, the mean (SD) age of the participants was 67.6 (10.7) years, and the mean (SD) body mass index was 25.7 (5.3). RMSTs were consistently higher for participants who underwent HCC surveillance (n = 975) (RMST difference at 1 year, 0.10 years [95% CI, 0.06-0.15 years]; P < .001; RMST difference at 3 years, 0.50 years [95% CI, 0.32-0.68 years]; P < .00...